172 results on '"Illert, Anna L."'
Search Results
2. Comprehensive genetic profiling and molecularly guided treatment for patients with primary CNS tumors
3. Expert-Guided Large Language Models for Clinical Decision Support in Precision Oncology
4. Precision Oncology: Grundlagen und Klassifikationen
5. Gene editing of hematopoietic stem cells restores T-cell response in familial hemophagocytic lymphohistiocytosis
6. Profile of the multicenter cohort of the German Cancer Consortium’s Clinical Communication Platform
7. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation
8. Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo
9. The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML
10. Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity
11. Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia
12. Primary results of patients with genitourinary malignancies presented at a Molecular Tumor Board
13. Blockade of tumor necrosis factor superfamily members CD30 and OX40 abrogates disease activity in murine immune-mediated glomerulonephritis
14. Precision Oncology: Grundlagen und Klassifikationen
15. CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges
16. Existence of reprogrammed lymphoma stem cells in a murine ALCL-like model
17. A novel conditional NPM-ALK-driven model of CD30+ T-cell lymphoma mediated by a translational stop cassette
18. Community-driven development of a modified progression-free survival ratio for precision oncology
19. MIRACUM-Pipe: An Adaptable Pipeline for Next-Generation Sequencing Analysis, Reporting, and Visualization for Clinical Decision Making
20. Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer
21. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
22. Abstract 926: Genomics-based personalized oncology of advanced thymic epithelial tumors
23. Data from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers
24. Supplementary Tables S1-S7 from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers
25. Supplementary Figures S1-S10 from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers
26. Supplementary Methods from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers
27. Mycobacteria exploit nitric oxide‐induced transformation of macrophages into permissive giant cells
28. Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms
29. Profile of the Multicenter Cohort of the German Cancer Consortium’s Clinical Communication Platform
30. Erratum To: Mycobacteria exploit nitric oxide‐induced transformation of macrophages into permissive giant cells
31. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation
32. Bcl‐x Las prognostic marker and potential therapeutic target in cholangiocarcinoma
33. Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany
34. Gene expression-based prediction of pazopanib efficacy in sarcoma
35. Abstract 945: Gab2 deficiency protects against Flt3-ITD driven acute myeloid leukemia in vivo
36. Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy (vol 135, pg 1, 2020)
37. Corrigendum to 'Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group Molecular Diagnostics and Therapy'
38. Corrigendum to “Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group ‘Molecular Diagnostics and Therapy’” [European Journal of Cancer 135 (2020) 1-7]
39. Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo
40. The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML
41. Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers
42. Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis
43. Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy'
44. Personalized Treatment Selection and Disease Monitoring Using Circulating Tumor DNA Profiling in Real-World Cancer Patient Management
45. Personalized Treatment Selection and Disease Monitoring Using Circulating Tumor DNA Profiling in Real-World Cancer Patient Management
46. Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group ‘Molecular Diagnostics and Therapy’
47. Erratum : Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
48. Corrigendum: Mycobacteria exploit nitric oxide-induced transformation of macrophages into permissive giant cells
49. A novel conditional NPM-ALK-driven model of CD30+ T-cell lymphoma mediated by a translational stop cassette
50. Proteomic Phosphosite Analysis Identified Crucial NPM-ALK-Mediated NIPA Serine and Threonine Residues
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.